Alpha-2 macroglobulin in Alzheimer's disease

A marker of neuronal injury through the RCAN1 pathway

V. R. Varma, S. Varma, Y. An, T. J. Hohman, S. Seddighi, R. Casanova, A. Beri, E. B. Dammer, N. T. Seyfried, Olga Pletnikova, Abhay R Moghekar, M. R. Wilson, J. J. Lah, R. J. O'Brien, A. I. Levey, Juan C Troncoso, Marilyn Albert, M. Thambisetty

Research output: Contribution to journalArticle

Abstract

Preclinical changes that precede the onset of symptoms and eventual diagnosis of Alzheimer's disease (AD) are a target for potential preventive interventions. A large body of evidence suggests that inflammation is closely associated with AD pathogenesis and may be a promising target pathway for such interventions. However, little is known about the association between systemic inflammation and preclinical AD pathophysiology. We first examined whether the acute-phase protein, alpha-2 macroglobulin (A2M), a major component of the innate immune system, was associated with cerebrospinal fluid (CSF) markers of neuronal injury in preclinical AD and risk of incident AD in the predictors of cognitive decline among normal individuals (BIOCARD) cohort. We find that A2M concentration in blood is significantly associated with CSF concentrations of the neuronal injury markers, tau and phosphorylated tau, and that higher baseline serum A2M concentration is associated with an almost threefold greater risk of progression to clinical symptoms of AD in men. These findings were replicated in the Alzheimer's Disease Neuroimaging (ADNI) study. Then, utilizing a systems level approach combining large multi-tissue gene expression datasets with mass spectrometry-based proteomic analyses of brain tissue, we identified an A2M gene network that includes regulator of calcineurin (RCAN1), an inhibitor of calcineurin, a well-characterized tau phosphatase. A2M gene and protein expression in the brain were significantly associated with gene and protein expression levels of calcineurin. Collectively these novel findings suggest that A2M is associated with preclinical AD, reflects early neuronal injury in the disease course and may be responsive to tau phosphorylation in the brain through the RCAN1-calcineurin pathway.

Original languageEnglish (US)
Pages (from-to)13-23
Number of pages11
JournalMolecular Psychiatry
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

alpha-Macroglobulins
Alzheimer Disease
Wounds and Injuries
Calcineurin
Gene Expression
Cerebrospinal Fluid
Brain
Inflammation
Acute-Phase Proteins
Gene Regulatory Networks
Phosphoric Monoester Hydrolases
Neuroimaging
Proteomics
Immune System
Mass Spectrometry
Proteins
Phosphorylation

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Varma, V. R., Varma, S., An, Y., Hohman, T. J., Seddighi, S., Casanova, R., ... Thambisetty, M. (2017). Alpha-2 macroglobulin in Alzheimer's disease: A marker of neuronal injury through the RCAN1 pathway. Molecular Psychiatry, 22(1), 13-23. https://doi.org/10.1038/mp.2016.206

Alpha-2 macroglobulin in Alzheimer's disease : A marker of neuronal injury through the RCAN1 pathway. / Varma, V. R.; Varma, S.; An, Y.; Hohman, T. J.; Seddighi, S.; Casanova, R.; Beri, A.; Dammer, E. B.; Seyfried, N. T.; Pletnikova, Olga; Moghekar, Abhay R; Wilson, M. R.; Lah, J. J.; O'Brien, R. J.; Levey, A. I.; Troncoso, Juan C; Albert, Marilyn; Thambisetty, M.

In: Molecular Psychiatry, Vol. 22, No. 1, 01.01.2017, p. 13-23.

Research output: Contribution to journalArticle

Varma, VR, Varma, S, An, Y, Hohman, TJ, Seddighi, S, Casanova, R, Beri, A, Dammer, EB, Seyfried, NT, Pletnikova, O, Moghekar, AR, Wilson, MR, Lah, JJ, O'Brien, RJ, Levey, AI, Troncoso, JC, Albert, M & Thambisetty, M 2017, 'Alpha-2 macroglobulin in Alzheimer's disease: A marker of neuronal injury through the RCAN1 pathway', Molecular Psychiatry, vol. 22, no. 1, pp. 13-23. https://doi.org/10.1038/mp.2016.206
Varma, V. R. ; Varma, S. ; An, Y. ; Hohman, T. J. ; Seddighi, S. ; Casanova, R. ; Beri, A. ; Dammer, E. B. ; Seyfried, N. T. ; Pletnikova, Olga ; Moghekar, Abhay R ; Wilson, M. R. ; Lah, J. J. ; O'Brien, R. J. ; Levey, A. I. ; Troncoso, Juan C ; Albert, Marilyn ; Thambisetty, M. / Alpha-2 macroglobulin in Alzheimer's disease : A marker of neuronal injury through the RCAN1 pathway. In: Molecular Psychiatry. 2017 ; Vol. 22, No. 1. pp. 13-23.
@article{8bd3f0535159481dab3edb79bb21903d,
title = "Alpha-2 macroglobulin in Alzheimer's disease: A marker of neuronal injury through the RCAN1 pathway",
abstract = "Preclinical changes that precede the onset of symptoms and eventual diagnosis of Alzheimer's disease (AD) are a target for potential preventive interventions. A large body of evidence suggests that inflammation is closely associated with AD pathogenesis and may be a promising target pathway for such interventions. However, little is known about the association between systemic inflammation and preclinical AD pathophysiology. We first examined whether the acute-phase protein, alpha-2 macroglobulin (A2M), a major component of the innate immune system, was associated with cerebrospinal fluid (CSF) markers of neuronal injury in preclinical AD and risk of incident AD in the predictors of cognitive decline among normal individuals (BIOCARD) cohort. We find that A2M concentration in blood is significantly associated with CSF concentrations of the neuronal injury markers, tau and phosphorylated tau, and that higher baseline serum A2M concentration is associated with an almost threefold greater risk of progression to clinical symptoms of AD in men. These findings were replicated in the Alzheimer's Disease Neuroimaging (ADNI) study. Then, utilizing a systems level approach combining large multi-tissue gene expression datasets with mass spectrometry-based proteomic analyses of brain tissue, we identified an A2M gene network that includes regulator of calcineurin (RCAN1), an inhibitor of calcineurin, a well-characterized tau phosphatase. A2M gene and protein expression in the brain were significantly associated with gene and protein expression levels of calcineurin. Collectively these novel findings suggest that A2M is associated with preclinical AD, reflects early neuronal injury in the disease course and may be responsive to tau phosphorylation in the brain through the RCAN1-calcineurin pathway.",
author = "Varma, {V. R.} and S. Varma and Y. An and Hohman, {T. J.} and S. Seddighi and R. Casanova and A. Beri and Dammer, {E. B.} and Seyfried, {N. T.} and Olga Pletnikova and Moghekar, {Abhay R} and Wilson, {M. R.} and Lah, {J. J.} and O'Brien, {R. J.} and Levey, {A. I.} and Troncoso, {Juan C} and Marilyn Albert and M. Thambisetty",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/mp.2016.206",
language = "English (US)",
volume = "22",
pages = "13--23",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Alpha-2 macroglobulin in Alzheimer's disease

T2 - A marker of neuronal injury through the RCAN1 pathway

AU - Varma, V. R.

AU - Varma, S.

AU - An, Y.

AU - Hohman, T. J.

AU - Seddighi, S.

AU - Casanova, R.

AU - Beri, A.

AU - Dammer, E. B.

AU - Seyfried, N. T.

AU - Pletnikova, Olga

AU - Moghekar, Abhay R

AU - Wilson, M. R.

AU - Lah, J. J.

AU - O'Brien, R. J.

AU - Levey, A. I.

AU - Troncoso, Juan C

AU - Albert, Marilyn

AU - Thambisetty, M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Preclinical changes that precede the onset of symptoms and eventual diagnosis of Alzheimer's disease (AD) are a target for potential preventive interventions. A large body of evidence suggests that inflammation is closely associated with AD pathogenesis and may be a promising target pathway for such interventions. However, little is known about the association between systemic inflammation and preclinical AD pathophysiology. We first examined whether the acute-phase protein, alpha-2 macroglobulin (A2M), a major component of the innate immune system, was associated with cerebrospinal fluid (CSF) markers of neuronal injury in preclinical AD and risk of incident AD in the predictors of cognitive decline among normal individuals (BIOCARD) cohort. We find that A2M concentration in blood is significantly associated with CSF concentrations of the neuronal injury markers, tau and phosphorylated tau, and that higher baseline serum A2M concentration is associated with an almost threefold greater risk of progression to clinical symptoms of AD in men. These findings were replicated in the Alzheimer's Disease Neuroimaging (ADNI) study. Then, utilizing a systems level approach combining large multi-tissue gene expression datasets with mass spectrometry-based proteomic analyses of brain tissue, we identified an A2M gene network that includes regulator of calcineurin (RCAN1), an inhibitor of calcineurin, a well-characterized tau phosphatase. A2M gene and protein expression in the brain were significantly associated with gene and protein expression levels of calcineurin. Collectively these novel findings suggest that A2M is associated with preclinical AD, reflects early neuronal injury in the disease course and may be responsive to tau phosphorylation in the brain through the RCAN1-calcineurin pathway.

AB - Preclinical changes that precede the onset of symptoms and eventual diagnosis of Alzheimer's disease (AD) are a target for potential preventive interventions. A large body of evidence suggests that inflammation is closely associated with AD pathogenesis and may be a promising target pathway for such interventions. However, little is known about the association between systemic inflammation and preclinical AD pathophysiology. We first examined whether the acute-phase protein, alpha-2 macroglobulin (A2M), a major component of the innate immune system, was associated with cerebrospinal fluid (CSF) markers of neuronal injury in preclinical AD and risk of incident AD in the predictors of cognitive decline among normal individuals (BIOCARD) cohort. We find that A2M concentration in blood is significantly associated with CSF concentrations of the neuronal injury markers, tau and phosphorylated tau, and that higher baseline serum A2M concentration is associated with an almost threefold greater risk of progression to clinical symptoms of AD in men. These findings were replicated in the Alzheimer's Disease Neuroimaging (ADNI) study. Then, utilizing a systems level approach combining large multi-tissue gene expression datasets with mass spectrometry-based proteomic analyses of brain tissue, we identified an A2M gene network that includes regulator of calcineurin (RCAN1), an inhibitor of calcineurin, a well-characterized tau phosphatase. A2M gene and protein expression in the brain were significantly associated with gene and protein expression levels of calcineurin. Collectively these novel findings suggest that A2M is associated with preclinical AD, reflects early neuronal injury in the disease course and may be responsive to tau phosphorylation in the brain through the RCAN1-calcineurin pathway.

UR - http://www.scopus.com/inward/record.url?scp=84996837281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996837281&partnerID=8YFLogxK

U2 - 10.1038/mp.2016.206

DO - 10.1038/mp.2016.206

M3 - Article

VL - 22

SP - 13

EP - 23

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -